Острый коронарный синдром и функция почек
Download
2. Burden R., Tomson C. Identification, management and referral of adults with chronic kidney disease: concise guidelines // Clin. Med. – 2005. – Vol. 5. – P. 635–642.
3. Kidney Disease Quality Outcomes Initiative. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification // Amer. J. Kidney Dis. – 2002. – Vol. 39, № 2 (Suppl. 1). – P. S1–S266.
4. Froissart M., Rossert J., Jacquot C. Predictive performance of the modification of diet in renal disease and Cockcroft–Gault equations for estimating renal function // J. Amer. Soc. Nephrol. – 2005. – Vol. 16. – P. 763–773.
5. Dharnidharka V., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis // Amer. J. Kidney Dis. – 2002. – Vol. 40. – P. 221–226.
6. Hojs R., Bevc S., Ekart R. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function // Nephrol. Dial. Transplant. – 2006. – Vol. 21. – P. 1855–1862.
7. Schuck O., Teplan V., Jabor A. Glomerular filtration rate estimation in patients with advanced chronic renal insufficiency based on serum cystatin C levels // Nephron Clin. Pract. – 2003. – Vol. 93. – P. c146–c151.
8. Hallan S., Dahl K., Oien C. Screening strategies for chronic kidney disease in the general population: follow- up of cross sectional health survey // Brit. Med. J. – 2006. – Vol. 333. – P. 1047.
9. Rahman M., Pressel S., Davis B. for the ALLHAT Collaborative Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate // Ann. Intern. Med. – 2006. – Vol. 144. – P. 172–180.
10. Go A., Chertow G., Fan D. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N. Engl. J. Med. – 2004. – Vol. 351. – P. 1296–1305.
11. Shlipak M., Fried L., Crump C. Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency // Circulation. – 2003. – Vol. 107. – P. 87.
12. Al Banchaabouchi M., Marescau B., D’Hooge R. Biochemical and histopathological changes in nephrectomized mice // Metabolism. – 1998. – Vol. 47. – P. 355–361.
13. Hernndez-Vargas P., Lуpez-Franco O., Sanjudn G. Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells // J. Amer. Soc. Nephrol. – 2005. – Vol. 16, № 60. – P. 1673–1683.
14. Wetmore J., Hung A., Lovett D. Interleukin-1 gene cluster polymorphisms predict risk of ESRD // Kidney Int. – 2005. – Vol. 68. – P. 278–284.
15. Fried L., Solomon C., Shlipak M. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals // J. Amer. Soc. Nephrol. – 2004. – Vol. 15, № 12. – P. 3184–3191.
16. Tonelli M., Sacks F., Pfeffer M., for the Investigators CaRECT. Biomarkers of inflammation and progression of chronic kidney disease // Kidney Int. – 2005. – Vol. 68. – P. 237–245.
17. Stuveling E., Hillege H., Bakker S. C-reactive protein is associated with renal function abnormalities in a non-diabetic population // Ibid. – 2003. – Vol. 63. – P. 654–661.
18. Sarnak M. Morbidity of inflammation in CKD. Program and abstracts of the American Society of Nephrology Renal Week 2006. – Nov. 13–19, 2006; San Diego, California.
19. Singh D., Whooley M., Shlipak M. Association of Cystatin C and Estimated GFR with Inflammatory Biomarkers: the Heart and Soul Study // Nephrol. Dial. Transplant. – 2007. – Vol. 22, № 4. – P. 1087–1092.
20. Fried L., Orchard T., Kasiske B., for the Lipids and Renal Disease Progression Meta-Analysis Study Group. Effect of lipid reduction on the progression of renal disease: a meta-analysis // Kidney Int. – 2001. – Vol. 59. – P. 260–269.
21. Shepherd J., Wenger N., for the TNT Steering Committee and Investigators. Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) Study. American College of Cardiology 2006 Scientific Sessions. – March 13, 2006; Atlanta, GA. (Abstr. 808).
22. Marenzi G., Moltrasio M., Assanelli E. Impact of Cardiac and Renal Dysfunction on Inhospital Morbidity and Mortality of Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty // Amer. Heart J. – 2007. – Vol. 153, № 5. – P. 755–762.
23. Schiele F., Legalery P., Didier K. Impact of Renal Dysfunction on 1-Year Mortality After Acute Myocardial Infarction // Ibid. – 2006. – Vol. 151, № 3. – P. 661–667.
24. Charytan D., Setoguchi S., Solomon D. Clinical Presentation of Myocardial Infarction Contributes to Lower Use of Coronary Angiography in Patients With Chronic Kidney Disease // Kidney Int. – 2007. – Vol. 71, № 9. – P. 938–945.
25. Johnson N., Jernberg T., Lagerqvist B. Early Invasive Treatment Benefits Patients With Renal Dysfunction in Unstable Coronary Artery Disease // Amer. Heart J. – 2006. – Vol. 152, № 6. – P. 1052–1058.
26. Davidson C., Stacul F., McCullough P. Contrast medium use//Amer. J. Cardiol. –2006.– Vol. 98.– P. 42.
27. Sisillo E., Ceriani R., Bortone F. N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial // Crit. Care Med. – 2008. – Vol. 36, № 1. – P. 81–86.
28. Briguori C., Airoldi F., D’Andrea D. et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies // Circulation. – 2007. – Vol. 115. – P. 1211–1217.
References
1. Masoudi F., Plomondon M., Magid D. Renal Insufficiency and Mortality From Acute Coronary Syndromes // Amer. Heart J. – 2004. – Vol. 147, № 4. – P. 623–629.2. Burden R., Tomson C. Identification, management and referral of adults with chronic kidney disease: concise guidelines // Clin. Med. – 2005. – Vol. 5. – P. 635–642.
3. Kidney Disease Quality Outcomes Initiative. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification // Amer. J. Kidney Dis. – 2002. – Vol. 39, № 2 (Suppl. 1). – P. S1–S266.
4. Froissart M., Rossert J., Jacquot C. Predictive performance of the modification of diet in renal disease and Cockcroft–Gault equations for estimating renal function // J. Amer. Soc. Nephrol. – 2005. – Vol. 16. – P. 763–773.
5. Dharnidharka V., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis // Amer. J. Kidney Dis. – 2002. – Vol. 40. – P. 221–226.
6. Hojs R., Bevc S., Ekart R. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function // Nephrol. Dial. Transplant. – 2006. – Vol. 21. – P. 1855–1862.
7. Schuck O., Teplan V., Jabor A. Glomerular filtration rate estimation in patients with advanced chronic renal insufficiency based on serum cystatin C levels // Nephron Clin. Pract. – 2003. – Vol. 93. – P. c146–c151.
8. Hallan S., Dahl K., Oien C. Screening strategies for chronic kidney disease in the general population: follow- up of cross sectional health survey // Brit. Med. J. – 2006. – Vol. 333. – P. 1047.
9. Rahman M., Pressel S., Davis B. for the ALLHAT Collaborative Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate // Ann. Intern. Med. – 2006. – Vol. 144. – P. 172–180.
10. Go A., Chertow G., Fan D. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N. Engl. J. Med. – 2004. – Vol. 351. – P. 1296–1305.
11. Shlipak M., Fried L., Crump C. Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency // Circulation. – 2003. – Vol. 107. – P. 87.
12. Al Banchaabouchi M., Marescau B., D’Hooge R. Biochemical and histopathological changes in nephrectomized mice // Metabolism. – 1998. – Vol. 47. – P. 355–361.
13. Hernndez-Vargas P., Lуpez-Franco O., Sanjudn G. Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells // J. Amer. Soc. Nephrol. – 2005. – Vol. 16, № 60. – P. 1673–1683.
14. Wetmore J., Hung A., Lovett D. Interleukin-1 gene cluster polymorphisms predict risk of ESRD // Kidney Int. – 2005. – Vol. 68. – P. 278–284.
15. Fried L., Solomon C., Shlipak M. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals // J. Amer. Soc. Nephrol. – 2004. – Vol. 15, № 12. – P. 3184–3191.
16. Tonelli M., Sacks F., Pfeffer M., for the Investigators CaRECT. Biomarkers of inflammation and progression of chronic kidney disease // Kidney Int. – 2005. – Vol. 68. – P. 237–245.
17. Stuveling E., Hillege H., Bakker S. C-reactive protein is associated with renal function abnormalities in a non-diabetic population // Ibid. – 2003. – Vol. 63. – P. 654–661.
18. Sarnak M. Morbidity of inflammation in CKD. Program and abstracts of the American Society of Nephrology Renal Week 2006. – Nov. 13–19, 2006; San Diego, California.
19. Singh D., Whooley M., Shlipak M. Association of Cystatin C and Estimated GFR with Inflammatory Biomarkers: the Heart and Soul Study // Nephrol. Dial. Transplant. – 2007. – Vol. 22, № 4. – P. 1087–1092.
20. Fried L., Orchard T., Kasiske B., for the Lipids and Renal Disease Progression Meta-Analysis Study Group. Effect of lipid reduction on the progression of renal disease: a meta-analysis // Kidney Int. – 2001. – Vol. 59. – P. 260–269.
21. Shepherd J., Wenger N., for the TNT Steering Committee and Investigators. Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) Study. American College of Cardiology 2006 Scientific Sessions. – March 13, 2006; Atlanta, GA. (Abstr. 808).
22. Marenzi G., Moltrasio M., Assanelli E. Impact of Cardiac and Renal Dysfunction on Inhospital Morbidity and Mortality of Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty // Amer. Heart J. – 2007. – Vol. 153, № 5. – P. 755–762.
23. Schiele F., Legalery P., Didier K. Impact of Renal Dysfunction on 1-Year Mortality After Acute Myocardial Infarction // Ibid. – 2006. – Vol. 151, № 3. – P. 661–667.
24. Charytan D., Setoguchi S., Solomon D. Clinical Presentation of Myocardial Infarction Contributes to Lower Use of Coronary Angiography in Patients With Chronic Kidney Disease // Kidney Int. – 2007. – Vol. 71, № 9. – P. 938–945.
25. Johnson N., Jernberg T., Lagerqvist B. Early Invasive Treatment Benefits Patients With Renal Dysfunction in Unstable Coronary Artery Disease // Amer. Heart J. – 2006. – Vol. 152, № 6. – P. 1052–1058.
26. Davidson C., Stacul F., McCullough P. Contrast medium use//Amer. J. Cardiol. –2006.– Vol. 98.– P. 42.
27. Sisillo E., Ceriani R., Bortone F. N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial // Crit. Care Med. – 2008. – Vol. 36, № 1. – P. 81–86.
28. Briguori C., Airoldi F., D’Andrea D. et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies // Circulation. – 2007. – Vol. 115. – P. 1211–1217.
